201 related articles for article (PubMed ID: 27196777)
1. NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer.
Li LS; Reddy S; Lin ZH; Liu S; Park H; Chun SG; Bornmann WG; Thibodeaux J; Yan J; Chakrabarti G; Xie XJ; Sumer BD; Boothman DA; Yordy JS
Mol Cancer Ther; 2016 Jul; 15(7):1757-67. PubMed ID: 27196777
[TBL] [Abstract][Full Text] [Related]
2. NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers.
Motea EA; Huang X; Singh N; Kilgore JA; Williams NS; Xie XJ; Gerber DE; Beg MS; Bey EA; Boothman DA
Clin Cancer Res; 2019 Apr; 25(8):2601-2609. PubMed ID: 30617135
[TBL] [Abstract][Full Text] [Related]
3. Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.
Cao L; Li LS; Spruell C; Xiao L; Chakrabarti G; Bey EA; Reinicke KE; Srougi MC; Moore Z; Dong Y; Vo P; Kabbani W; Yang CR; Wang X; Fattah F; Morales JC; Motea EA; Bornmann WG; Yordy JS; Boothman DA
Antioxid Redox Signal; 2014 Jul; 21(2):237-50. PubMed ID: 24512128
[TBL] [Abstract][Full Text] [Related]
4. Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.
Chakrabarti G; Silvers MA; Ilcheva M; Liu Y; Moore ZR; Luo X; Gao J; Anderson G; Liu L; Sarode V; Gerber DE; Burma S; DeBerardinis RJ; Gerson SL; Boothman DA
Sci Rep; 2015 Nov; 5():17066. PubMed ID: 26602448
[TBL] [Abstract][Full Text] [Related]
5. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.
Bey EA; Reinicke KE; Srougi MC; Varnes M; Anderson VE; Pink JJ; Li LS; Patel M; Cao L; Moore Z; Rommel A; Boatman M; Lewis C; Euhus DM; Bornmann WG; Buchsbaum DJ; Spitz DR; Gao J; Boothman DA
Mol Cancer Ther; 2013 Oct; 12(10):2110-20. PubMed ID: 23883585
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation.
Park HJ; Ahn KJ; Ahn SD; Choi E; Lee SW; Williams B; Kim EJ; Griffin R; Bey EA; Bornmann WG; Gao J; Park HJ; Boothman DA; Song CW
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):212-9. PubMed ID: 15629614
[TBL] [Abstract][Full Text] [Related]
7. β-lapachone significantly increases the effect of ionizing radiation to cause mitochondrial apoptosis via JNK activation in cancer cells.
Park MT; Song MJ; Lee H; Oh ET; Choi BH; Jeong SY; Choi EK; Park HJ
PLoS One; 2011; 6(10):e25976. PubMed ID: 21998736
[TBL] [Abstract][Full Text] [Related]
8. NAD(P)H:quinone oxidoreductase 1 determines radiosensitivity of triple negative breast cancer cells and is controlled by long non-coding RNA NEAT1.
Lin LC; Lee HT; Chien PJ; Huang YH; Chang MY; Lee YC; Chang WW
Int J Med Sci; 2020; 17(14):2214-2224. PubMed ID: 32922184
[TBL] [Abstract][Full Text] [Related]
9. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.
Li LS; Bey EA; Dong Y; Meng J; Patra B; Yan J; Xie XJ; Brekken RA; Barnett CC; Bornmann WG; Gao J; Boothman DA
Clin Cancer Res; 2011 Jan; 17(2):275-85. PubMed ID: 21224367
[TBL] [Abstract][Full Text] [Related]
10. Beta-lapachone suppresses radiation-induced activation of nuclear factor-kappaB.
Dong GZ; Oh ET; Lee H; Park MT; Song CW; Park HJ
Exp Mol Med; 2010 May; 42(5):327-34. PubMed ID: 20200474
[TBL] [Abstract][Full Text] [Related]
11. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
Huang X; Dong Y; Bey EA; Kilgore JA; Bair JS; Li LS; Patel M; Parkinson EI; Wang Y; Williams NS; Gao J; Hergenrother PJ; Boothman DA
Cancer Res; 2012 Jun; 72(12):3038-47. PubMed ID: 22532167
[TBL] [Abstract][Full Text] [Related]
12. β-Lapachone promotes the recruitment and polarization of tumor-associated neutrophils (TANs) toward an antitumor (N1) phenotype in NQO1-positive cancers.
Tumbath S; Jiang L; Li X; Zhang T; Zahid KR; Zhao Y; Zhou H; Yin Z; Lu T; Jiang S; Chen Y; Chen X; Fu YX; Huang X
Oncoimmunology; 2024; 13(1):2363000. PubMed ID: 38846085
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells.
Choi EK; Terai K; Ji IM; Kook YH; Park KH; Oh ET; Griffin RJ; Lim BU; Kim JS; Lee DS; Boothman DA; Loren M; Song CW; Park HJ
Neoplasia; 2007 Aug; 9(8):634-42. PubMed ID: 17786182
[TBL] [Abstract][Full Text] [Related]
14. NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone.
Moore Z; Chakrabarti G; Luo X; Ali A; Hu Z; Fattah FJ; Vemireddy R; DeBerardinis RJ; Brekken RA; Boothman DA
Cell Death Dis; 2015 Jan; 6(1):e1599. PubMed ID: 25590809
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation.
Dong Y; Bey EA; Li LS; Kabbani W; Yan J; Xie XJ; Hsieh JT; Gao J; Boothman DA
Cancer Res; 2010 Oct; 70(20):8088-96. PubMed ID: 20940411
[TBL] [Abstract][Full Text] [Related]
16. Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.
Huang X; Motea EA; Moore ZR; Yao J; Dong Y; Chakrabarti G; Kilgore JA; Silvers MA; Patidar PL; Cholka A; Fattah F; Cha Y; Anderson GG; Kusko R; Peyton M; Yan J; Xie XJ; Sarode V; Williams NS; Minna JD; Beg M; Gerber DE; Bey EA; Boothman DA
Cancer Cell; 2016 Dec; 30(6):940-952. PubMed ID: 27960087
[TBL] [Abstract][Full Text] [Related]
17. Albumin binding revitalizes NQO1 bioactivatable drugs as novel therapeutics for pancreatic cancer.
Dou L; Liu H; Wang K; Liu J; Liu L; Ye J; Wang R; Deng H; Qian F
J Control Release; 2022 Sep; 349():876-889. PubMed ID: 35907592
[TBL] [Abstract][Full Text] [Related]
18. Cellular and molecular responses to topoisomerase I poisons. Exploiting synergy for improved radiotherapy.
Miyamoto S; Huang TT; Wuerzberger-Davis S; Bornmann WG; Pink JJ; Tagliarino C; Kinsella TJ; Boothman DA
Ann N Y Acad Sci; 2000; 922():274-92. PubMed ID: 11193903
[TBL] [Abstract][Full Text] [Related]
19. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism.
Silvers MA; Deja S; Singh N; Egnatchik RA; Sudderth J; Luo X; Beg MS; Burgess SC; DeBerardinis RJ; Boothman DA; Merritt ME
J Biol Chem; 2017 Nov; 292(44):18203-18216. PubMed ID: 28916726
[TBL] [Abstract][Full Text] [Related]
20. PCNA inhibition enhances the cytotoxicity of β-lapachone in NQO1-Positive cancer cells by augmentation of oxidative stress-induced DNA damage.
Su X; Wang J; Jiang L; Chen Y; Lu T; Mendonca MS; Huang X
Cancer Lett; 2021 Oct; 519():304-314. PubMed ID: 34329742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]